obesity drug news today glp-1 oct 27 2025 Market GLP-1 Spending Hit $5.8 Billion

Common versions include tirzapetide (Mounjaro/Zepbound), semaglutide (Ozempic/Wegovy/Rybelsus) and are available orally or subcutaneously (injections)

From the approval of Orlistat (Xenical) in 1999, which focused on reducing dietary fat absorption, to the emergence of highly effective incretin-based therapies such as liraglutide (Saxenda), semaglutide (Wegovy), and tirzepatide (Zepbound), we have witnessed a fundamental shift in how obesity is understood and treated

FDA-Approved Indications GLP-1 agonists (also known as GLP-1 receptor agonists, incretin mimetics, or GLP-1 analogs) represent a class of medications used to treat T2DM and, in some cases,

University of Cincinnati researchers, funded by the NIH, are studying how GLP-1 drugs may help prevent Alzheimers disease by analyzing real-world data from patients with mild cognitive impairment

GLP-1 (glucagon-like peptide-1) is a hormone that plays a crucial role in regulating blood sugar levels and appetite

Health and wellness company Hims & Hers announced Monday that it is introducing injectable weight-loss drugs at a fraction of the cost of Ozempic and Wegovy.